Safety assessment study of ET-743 in patients with translocation-related sarcomas
Phase 2
- Conditions
- Patients with malignant soft tissue sarcomas of histological types that have been reported to carry chromosomal translocations
- Registration Number
- JPRN-jRCT2080222464
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Any of translocation-related sarcomas histopathologically confirmed at the study site
Unresponsiveness or intolerability to the standard chemotherapy regimens
Other
Exclusion Criteria
Severe concurrent disease
Other
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method